Pilot study of anxiolytic drug Lodixem in patients with acute decompensed heart failure

Cardiovascular surgeon, Gastroenterologist, Endocrinologist, Infectious disease, Cardiologist, Expert in narcology, Neurologist, General practitioner

Anxiety disorders often accompany the course of cardiovascular disease and become more pronounced as they progress. Anxiety is also a frequent companion of patients with heart failure (HF). In a recent meta-analysis of 38 studies by K. Easton et al. (2015) estimated that 32% of patients with HF experience an increased level of anxiety, and 13% of patients meet the criteria for anxiety disorder. In the later stages of heart failure, the prevalence of anxiety increases. Anxiety disorder is diagnosed in approximately 20% of patients with decompensated HF who require implantation of auxiliary devices to maintain left ventricular function [5, 6].

Keywords: anxiety disorders, heart failure, emoxipin.

Authors:

L.G. Voronkov, MD, Professor, L.P. Paraschenyuk, G.Ye. Dudnyk, SI “NSC” Institute of Cardiology. Academician MD Strazheska “National Academy of Medical Sciences of Ukraine”, Kyiv

Literature:

  1. Ceiano C.M., Daunis D.J., Lokko H.N. et al. Anxiety disorders and cardiovascular disease. Curr. Psychiatry Rep. 2016. Nov; 18 (11): 101.
  2. Kawachi I., Sparrow D., Vokonas P., Weis S. Decreased heart rate variability in men with phobic anxiety (data from the Normative Aging Study). Am. J. Cardiol. 1995; vol. 75 (14): 882-885.
  3. Bankier B., Barajas J., Martinez-Rumayor A., Januzzi J. Association between C-reactive protein and generalized anxiety disorder in stable coronary heart disease patients. Eur. Heart J. 2008; vol. 29 (18): 2212-2217.
  4. Mercer D., Lavoie K., Ditto B. et al. The interaction between anxietyand depressive symptoms on brachial artery reactivity in cardiac patients. Biol. Psychol. 2014; vol. 102: 44-50.
  5. Strike P., Magid K., Brydon L. et al. Exaggerated platelet and hemodynamic reactivity to mental stress in men with coronary artery disease. Psychosom. Med. 2004; vol. 66 (4): 492-500.
  6. Gerritsen J., Dekker J., Ten Voorde B. et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular diseases: the Hoorn Study. Diabetes Care. 2001; vol. 24 (10): 1793-1798.
  7. Yapislar H., Aydogan S., Ozum U. Biological understanding of the cardiovascular risk associated with major depression and panic disorder isimportant. Int. J. Psychiatry. Clin. Pract. 2012; vol. 16 (1): 27-32.
  8. Васюк А., Довженко Т., Семиглазова М., Краснов В. Тревожно-депрессивные расстройства и сердечно-сосудистые заболевания: клинические взаимосвязи и современные подходы к терапии. Сердце: журнал для практикующих врачей. 2012; т.11, № 3 (65).
  9. Смирнов А.В., Нестерова О.Б., Голубев Р.В. Янтарная кислота и ее применение в медицине. Часть II. Применение янтарной кислоты в медицине. Нефрология. 2014; т. 18, № 4: 12-24.
  10. Лукьянова Л.Д., Атабаева Р.Е., Шепелева С.Ю. Биоэнергетические механизмы антигипоксического действия сукцинатсодержащего производного 3-окипиридина мексидола. Бюлл. экспер. биол. и мед. 1993; № 115 (3): 366-367.
  11. Лукьянова Л.Д., Романова В.Е., Чернобаева Г.Н. и др. Особенности антигипоксического действия мексидола связанные с его специфическим влиянием на энергетический обмен. Хим.-фарм. журнал. 1990; № 24 (8): 9-11.
  12. Sakamoto M., Takeshihe K., Yasui H., Tokunaga K. Cardioprotective effect of succinate against ischemia/reperfusion injury. Surg. Today. 1998; vol. 28 (5): 522-528.
  13. Cairns C.B., Ferroggiaro A.A., Walther J.M. et al. Postishemic administration of succinate reverses the impairment of oxidative phosphorylation after cardiac ischemia and reperfusion injury. Circulation. 1997; vol. 96 (Suppl. 9): 260-265.
  14. Смирнов Л.Д., Дюмаев К.М. 3-оксипроизводные шестичленных азотистых гетероциклов. Синтез, ингибирующая активность ибиологические свойства. Хим.-фарм. журнал. 1982; № 16 (4): 28-44.
  15. Ben-Ari G., Gaiarsa J., Tysio R., Khazipov R. GABA, a pioneer transmitter that exites immature neurons and generates primive oscillations. Physiol. Rev., 2007; v. 87: 1215-1284.
  16. Purves D., Augustine G., Fitzpatrick D. et al. Neuroscience (4th ed), Sinauer Assoc. 2008: 121-122.
  17. Оганов Р.Г. Положительный опыт применения этилметилгидроксипиридина сукцината в лечении кардиологических больных. Кардиоваскулярная терапия и профилактика. 2017; № 16 (5): 91-94.
  18. Sidorenko G.L., Komissarova S.M., Zolotukhina S.F. et al. The use of ethylmethydoxypyridine succinate in the treatment of patients with heart failure. Kardiologiia. 2011; vol. 6: 44-48.
  19. Borovkova N.Yu., Il’ina A.S., Spassky A.A. et al. Cytoprotective therapy for kidney injury in patients with ST-elevation myocardial. Cardiology and Cardiovascular Surgery. 2017; vol. 1: 38-41.
  20. Statsenko M.E., Evtereva E.D., Turkina S.V. et al. New possibilities of mexicor in the treatment of chronic heart failure in patients with metabolic syndrome. Russian J. Cardiology. 2010; vol. 6 (86): 28-33.
  21. Курята А.В., Карапетян К.Г., Бардаченко Н.П. и др. Возможности коррекции когнитивных функций и тревожно-депрессивных расстройств в комплексной терапии артериальной гипертензии в зависимости от функционального состояния почек. Журн. неврол. им. Н.Б. Маньковского. 2015; т. 3, № 3: 5-10.
  22. Бурчинский С.Г. Комплексная коррекция тревожных и когнитивных расстройств в ангионеврологии: цели, задачи, инструменты. Международный неврологический журнал. 2017; 8 (94).
  23. Heitzer T., Schlinzig T., Krohn K., Meinertz T., Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events inpatients with coronary artery disease. Circulation. 2001; 104 (22): 2673-2678.
  24. Drexler H. Endothelial dysfunction: clinical implications. Prog. Cardiovasc. Dis. 1997; 39 (4): 287-324.
  25. Narita K., Murata T., Hamada T. et al. Interactions among higher trait anxiety, sympathetic activity, and endothelial function in the elderly. J. Psychiatr. Res. 2007; 41 (5): 418-427.
  26. Mercer D., Lavoie K., Ditto B. et al. The interaction between anxiety and depressive symptoms on brachial artery reactivity in cardiac patients. Biol. Psychol. 2014; 102: 44-50.
  27. Harris K., Matthews K., Sutton-Tyrrell K., Kuller L. Associations between psychological traits and endothelial function in postmenopausal women. Psychosom. Med. 2003; 65 (3): 402-409.
  28. Felice F., Di Stefano R., Pini S. et al. Influence of depression and anxiety on circulating endothelial progenitor cells in patients with acute coronary syndromes. Hum. Psychopharmacol. 2015; 30 (3): 183-188. doi: 10.1002/hup.2470.
  29. von Kanel R., Hepp U., Traber R. et al. Measures of endothelial dysfunction in plasma of patients with posttraumatic stress disorder. Psychiatry Res. 2008; 158 (3): 363-373.
  30. Коновалова Е.Л. Актуальные проблемы медицины – 2012. Коррекция эндотелиальной дисфункции комбинацией L-норвалина и мексидола.
  31. Баженова Л.Н., Володина Н.Н., Фролова Н.П. Влияние препарата Mексидол на эндотелиальную дисфункцию у больных с хронической сердечной недостаточностью. Бюллетень экспериментальной биологии и медицины. 2006, приложение 1.
  32. Vane J., Enggard E., Batting R. Regulatory function of the vascular endothelium. N. Engl. J. Med. 1999; 323: 27-36.
  33. Дисфункция эндотелия. Причины, механизмы, фармакологическая коррекция // Под ред. И.Н. Петрищева. – Санкт-Петербург, 2003.– 184 с.
  34. Onder R., Barutcuoglu B. The endotelium. Milano, 2006. – 149 p.
  35. Березин А.Е. Биологические маркеры кардиоваскулярных заболеваний. Диагностическое и прогностическое значение биомаркеров стратификации пациентов с кардиометаболическим риском. – М., 2015. Lambert Academic Publishing GmbH. – 307 c.
  36. Lekakis J., Abraham P., Balbarini A. et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur. J. Cardiovasc. Prev. Rehabil. 2011; vol. 18: 775-789.
  37. Пархоменко А.Н., Иркин О.И., Лутай Я.М. и др. Эндотелиальная дисфункция у больных с острым инфарктом миокарда: связь стечением заболевания. Укр. кардіол. журнал, 2013; № 4 (додаток): 165-166.
  38. Berrazueta J., Guera-Ruiz A., Garsia-Unzueta M. et al. Endothelial dysfunction, measured by reactive hyperaemia using strain-gauge plethysmography, is an independent predictor of adverse outcome in heart failure. Eur. J. Heart Failure. 2010; vol. 12: 477-483.
  39. Fisher D., Rossa S., Landmesser U. et al. Endotelial dysfunction in patients with chronic heart failure is independently associated with increased evidence of hospitalization, cardiotransplantation, or death. Europ. Heart J. 2005; 26: 65-69.

Learn more

General practitioner

Correction of Iron Deficiency in Patients with CHF: Update of Practical Recommendations

Abstract. The European Society of Cardiology considers iron deficiency as a common comorbid condition in chronic heart failure (CHF) and provides recommendations for its diagnosis and treatment. Nevertheless, in clinical practice, even in developed countries, iron deficiency remains unnoticed by clinicians, and many patients with CHF do not receive replacement therapy, which can positively affect...
Cardiologist

Patients with cardiovascular diseases – diagnosis and correction of iron deficiency conditions

The latent iron deficiency among the adult population, even in European countries, is 30-40%. At the same time very often, iron deficiency is confused with anemia. That is why in this context it is appropriate to draw a parallel with the captain of the Titanic, who saw only the tip of the iceberg, and therefore...